vs
Side-by-side financial comparison of BONK, INC. (BNKK) and Mind Medicine (MindMed) Inc. (DFTX). Click either name above to swap in a different company.
Mind Medicine (MindMed) Inc. is the larger business by last-quarter revenue ($906.0K vs $515.4K, roughly 1.8× BONK, INC.). Mind Medicine (MindMed) Inc. runs the higher net margin — -2634.0% vs -8274.9%, a 5640.9% gap on every dollar of revenue. On growth, BONK, INC. posted the faster year-over-year revenue change (278.2% vs -16.1%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
BNKK vs DFTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $515.4K | $906.0K |
| Net Profit | $-42.7M | $-23.9M |
| Gross Margin | — | — |
| Operating Margin | — | -2450.8% |
| Net Margin | -8274.9% | -2634.0% |
| Revenue YoY | 278.2% | -16.1% |
| Net Profit YoY | -215.2% | -386.7% |
| EPS (diluted) | — | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $515.4K | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $44.9K | — | ||
| Q1 25 | $42.1K | — | ||
| Q4 24 | $-289.2K | — | ||
| Q3 24 | $110.2K | — | ||
| Q2 24 | $710.2K | — | ||
| Q1 24 | $170.7K | — |
| Q4 25 | $-42.7M | — | ||
| Q3 25 | $-33.6M | — | ||
| Q2 25 | $13.4M | — | ||
| Q1 25 | $-5.3M | — | ||
| Q4 24 | $-13.5M | — | ||
| Q3 24 | $-11.9M | — | ||
| Q2 24 | $-8.3M | — | ||
| Q1 24 | $-15.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 53.1% | — | ||
| Q1 25 | 49.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 29.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | -8274.9% | — | ||
| Q3 25 | -2216.8% | — | ||
| Q2 25 | 29756.5% | — | ||
| Q1 25 | -12652.7% | — | ||
| Q4 24 | 4678.7% | — | ||
| Q3 24 | -10823.8% | — | ||
| Q2 24 | -1165.0% | — | ||
| Q1 24 | -9180.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0.09 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $-31.07 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.16 | — | ||
| Q1 24 | $-0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $54.7K | $99.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.0M | $78.1M |
| Total Assets | $41.0M | $124.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.7K | — | ||
| Q3 25 | $54.7K | — | ||
| Q2 25 | $54.7K | — | ||
| Q1 25 | $54.7K | — | ||
| Q4 24 | $54.7K | — | ||
| Q3 24 | $54.7K | — | ||
| Q2 24 | $54.7K | — | ||
| Q1 24 | $242.6K | — |
| Q4 25 | $35.0M | — | ||
| Q3 25 | $75.5M | — | ||
| Q2 25 | $23.1M | — | ||
| Q1 25 | $-542.6K | — | ||
| Q4 24 | $-2.2M | — | ||
| Q3 24 | $6.4M | — | ||
| Q2 24 | $6.5M | — | ||
| Q1 24 | $5.6M | — |
| Q4 25 | $41.0M | — | ||
| Q3 25 | $81.0M | — | ||
| Q2 25 | $42.1M | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $7.3M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $9.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-20.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-4.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-5.1M | — | ||
| Q2 24 | $-5.7M | — | ||
| Q1 24 | $-6.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.12× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
